<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158140</url>
  </required_header>
  <id_info>
    <org_study_id>V110-911</org_study_id>
    <secondary_id>V110-911</secondary_id>
    <nct_id>NCT05158140</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine With a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger&#xD;
      ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active&#xD;
      immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory&#xD;
      syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine for&#xD;
      the prevention of pneumococcal disease (V110) and, a 15-valent pneumococcal conjugate vaccine&#xD;
      (PCV) indicated for the prevention of invasive pneumococcal disease (V114).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 12, 2022</start_date>
  <completion_date type="Anticipated">January 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with solicited injection-site adverse events (AEs)</measure>
    <time_frame>Up to Day 7 after any vaccination</time_frame>
    <description>Percentage of participants with solicited injection-site AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with solicited systemic AEs</measure>
    <time_frame>Up to Day 7 after any vaccination</time_frame>
    <description>Percentage of participants with solicited systemic AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with vaccine-related serious AEs (SAEs)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Percentage of participants with vaccine-related SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opsonophagocytic activity (OPA) Geometric mean titer (GMT) with V110</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Serotype-specific OPA GMT with V110</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OPA GMT with V114</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Serotype-specific OPA GMT with V114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2-specific binding antibody (bAb) GMT</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>SARS-CoV-2-specific bAb GMT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OPA geometric mean fold rise (GMFR) with V110</measure>
    <time_frame>Baseline and up to Day 60</time_frame>
    <description>Serotype-specific OPA GMFR with V110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPA GMFR with V114</measure>
    <time_frame>Baseline and up to Day 60</time_frame>
    <description>Serotype-specific OPA GMFR with V114</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with a change from baseline in OPA with V110</measure>
    <time_frame>Baseline and up to Day 60</time_frame>
    <description>Percentage of participants with a ≥4-fold change from baseline in serotype-specific OPA with V110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with a change from baseline in OPA with V114</measure>
    <time_frame>Baseline and up to Day 60</time_frame>
    <description>Percentage of participants with a ≥4-fold change from baseline in serotype-specific OPA with V114</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2-specific bAb GMFR</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>SARS-CoV-2-specific bAb GMFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with a change from baseline in SARS-CoV-2-specific bAb GMFR</measure>
    <time_frame>Baseline and Day 30</time_frame>
    <description>Percentage of participants with a ≥4-fold change from baseline in SARS-CoV-2-specific bAB GMFR</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Pneumococcal Infection</condition>
  <arm_group>
    <arm_group_label>V110 + concomitant mRNA-1273</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose vaccination of V110 concomitantly with a single dose vaccination of mRNA-1273 on Day 1, followed by a single dose vaccination of placebo for V110 on Day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V110 + non-concomitant mRNA-1273</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose vaccination of placebo for V110 on Day 1 concomitantly with a single dose vaccination of mRNA-1273, followed by a single dose vaccination of V110 on Day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 + concomitant mRNA-1273</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose vaccination of V114 concomitantly with a single dose vaccination of mRNA-1273 on Day 1, followed by a single dose vaccination of placebo for V114 on Day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 + non-concomitant mRNA-1273</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose vaccination of placebo for V114 on Day 1 concomitantly with a single dose vaccination of mRNA-1273, followed by a single dose vaccination of V114 on Day 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V110</intervention_name>
    <description>Single intramuscular (IM) dose of 0.5 mL V110 a pneumococcal polysaccharide vaccine containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F</description>
    <arm_group_label>V110 + concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V110 + non-concomitant mRNA-1273</arm_group_label>
    <other_name>PNEUMOVAX™23</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F</description>
    <arm_group_label>V114 + concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V114 + non-concomitant mRNA-1273</arm_group_label>
    <other_name>VAXNEUVANCE™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273</intervention_name>
    <description>Single IM dose of 50 μg/0.5 mL mRNA-1273</description>
    <arm_group_label>V110 + concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V110 + non-concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V114 + concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V114 + non-concomitant mRNA-1273</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for V110</intervention_name>
    <description>Single IM dose of 0.5 mL placebo for V110</description>
    <arm_group_label>V110 + concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V110 + non-concomitant mRNA-1273</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for V114</intervention_name>
    <description>Single IM dose of 0.5 mL placebo for V114</description>
    <arm_group_label>V114 + concomitant mRNA-1273</arm_group_label>
    <arm_group_label>V114 + non-concomitant mRNA-1273</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is in good health. Any underlying chronic illness must be documented to be in stable&#xD;
             condition.&#xD;
&#xD;
          -  Has received a 2-dose regimen of the Moderna mRNA SARS-CoV-2 vaccine ≥6 months before&#xD;
             enrollment.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies: Is not a woman of&#xD;
             childbearing potential (WOCBP) OR Is a WOCBP and using an acceptable contraceptive&#xD;
             method, or is abstinent from heterosexual intercourse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a current or known history of SARS-CoV-2 infection.&#xD;
&#xD;
          -  Has a history of myocarditis and/or pericarditis.&#xD;
&#xD;
          -  Has a known or suspected impairment of immunological function including, but not&#xD;
             limited to, a history of congenital or acquired immunodeficiency, documented human&#xD;
             immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  Has a coagulation disorder contraindicating intramuscular vaccinations.&#xD;
&#xD;
          -  Had a recent illness with fever (defined as oral or tympanic temperature ≥100.4°F&#xD;
             [≥38.0°C]; axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic&#xD;
             therapy for an acute illness occurring &lt;72 hours before receipt of study vaccine.&#xD;
&#xD;
          -  Has a known malignancy that is progressing or has required active treatment &lt;3 years&#xD;
             before enrollment.&#xD;
&#xD;
          -  Received prior administration of a pneumococcal polysaccharide vaccine &lt;5 years before&#xD;
             study enrollment or is expected to receive a pneumococcal polysaccharide vaccine&#xD;
             during the study outside the protocol.&#xD;
&#xD;
          -  Received prior administration of a PCV &lt;1 year before study enrollment or is expected&#xD;
             to receive a PCV during the study outside the protocol.&#xD;
&#xD;
          -  Received prior administration of any SARS-CoV-2 vaccine other than the 2-dose regimen&#xD;
             of the Moderna mRNA vaccine, or is expected to receive any SARS-CoV-2 vaccine during&#xD;
             the study outside the protocol.&#xD;
&#xD;
          -  Received systemic corticosteroids for ≥14 consecutive days and has not completed&#xD;
             intervention ≥30 days before study enrollment.&#xD;
&#xD;
          -  Received systemic corticosteroids exceeding physiologic replacement doses ≤14 days&#xD;
             before receipt of study vaccine.&#xD;
&#xD;
          -  Is currently receiving immunosuppressive therapy, including chemotherapeutic agents&#xD;
             used to treat cancer or other conditions, and interventions associated with organ or&#xD;
             bone marrow transplantation, or autoimmune disease.&#xD;
&#xD;
          -  Received any non-live vaccine ≤14 days before receipt of study vaccine or is scheduled&#xD;
             to receive any non-live vaccine ≤30 days after receipt of study vaccine. Exception:&#xD;
             Inactivated influenza vaccine allowed if given ≥7 days before or ≥15 days after&#xD;
             receipt of study vaccine.&#xD;
&#xD;
          -  Received any live virus vaccine ≤30 days before receipt of study vaccine or is&#xD;
             scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine.&#xD;
&#xD;
          -  Received a blood transfusion or blood products (including globulin) ≤6 months before&#xD;
             receipt of study vaccine or is scheduled to receive a blood transfusion or blood&#xD;
             product ≤30 days after receipt of study vaccine.&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical study&#xD;
             with an investigational compound or device within 2 months of participating in this&#xD;
             current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

